4-(3-((6-methyl-2-phenylpyrimidin-4-yl)oxy)propyl)morpholine

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(3-((6-methyl-2-phenylpyrimidin-4-yl)oxy)propyl)morpholine
• 英文别名: 4-methyl-2-phenyl-6-(3-(morpholin-1-yl)propoxy)pyrimidine；4-[3-(6-Methyl-2-phenylpyrimidin-4-yl)oxypropyl]morpholine；4-[3-(6-methyl-2-phenylpyrimidin-4-yl)oxypropyl]morpholine
• 化学式: C₁₈H₂₃N₃O₂
• 分子量: 313.4
• InChiKey: HJDSPOTXQZRDDK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  47.5
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  6-甲基-2-苯基嘧啶-4-酮 在 potassium carbonate 、 caesium carbonate 作用下， 以 丙酮 、 乙腈 为溶剂， 生成 4-(3-((6-methyl-2-phenylpyrimidin-4-yl)oxy)propyl)morpholine
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Novel Sigma-1 Receptor Antagonists Based on Pyrimidine Scaffold As Agents for Treating Neuropathic Pain

  摘要：

  The discovery and synthesis of a new series of pyrimidines as potent sigma-1 receptor (sigma R-1) antagonists, associated with pharmacological antineuropathic pain activity, are the focus of this article. The new compounds were evaluated in vitro in sigma-1 and sigma-2 receptor binding assays. The nature of the pyrimidine scaffold was crucial for activity, and a basic amine was shown to be necessary according to the known pharmacophoric model. The most promising derivative was 5-chloro-2-(4-chlorophenyl)-4-methyl-6-(3-(piperidin-1-yl)propoxy)pyrimidine (137), which exhibited a high binding affinity to sigma R-1 receptor (K-i sigma(1) = 1.06 nM) and good sigma-1/2 selectivity (1344-fold). In in vivo tests, compound 137 exerted dose-dependent antinociceptive effects in mice formalin model and rats CCI models of neuropathic pain. In addition, no motor impairments were found in rotarod tests; acceptable pharmacokinetic properties were also noted. These data suggest compound 137 may constitute a novel class of drugs for the treatment of neuropathic pain.

  DOI：

  10.1021/jm501207r

文献信息

• Synthesis and Biological Evaluation of Novel Sigma-1 Receptor Antagonists Based on Pyrimidine Scaffold As Agents for Treating Neuropathic Pain
  作者：Yu Lan、Yin Chen、Xudong Cao、Juecheng Zhang、Jie Wang、Xiangqing Xu、Yinli Qiu、Tan Zhang、Xin Liu、Bi-Feng Liu、Guisen Zhang

  DOI：10.1021/jm501207r

  日期：2014.12.26

  The discovery and synthesis of a new series of pyrimidines as potent sigma-1 receptor (sigma R-1) antagonists, associated with pharmacological antineuropathic pain activity, are the focus of this article. The new compounds were evaluated in vitro in sigma-1 and sigma-2 receptor binding assays. The nature of the pyrimidine scaffold was crucial for activity, and a basic amine was shown to be necessary according to the known pharmacophoric model. The most promising derivative was 5-chloro-2-(4-chlorophenyl)-4-methyl-6-(3-(piperidin-1-yl)propoxy)pyrimidine (137), which exhibited a high binding affinity to sigma R-1 receptor (K-i sigma(1) = 1.06 nM) and good sigma-1/2 selectivity (1344-fold). In in vivo tests, compound 137 exerted dose-dependent antinociceptive effects in mice formalin model and rats CCI models of neuropathic pain. In addition, no motor impairments were found in rotarod tests; acceptable pharmacokinetic properties were also noted. These data suggest compound 137 may constitute a novel class of drugs for the treatment of neuropathic pain.